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Abstract
Introduction: Aim 1 characterized sex differences and the role of ovarian hormones in
physical signs and negative affective states produced by nicotine withdrawal in female,
ovariectomized female (OVX), and male rats. We also compared nicotine withdrawal and
corticosterone levels with estradiol (E2) and progesterone across the 4-day estrous cycle. Aim 2
validated the role of ovarian hormones in withdrawal in OVX females that received vehicle, E2,
or E2+progesterone. Methods: Female rats received a sham surgery or an ovariectomy procedure.
Fifteen days later, all rats were implanted with a pump that delivered nicotine for 14 days. On the
test day, separate groups received saline or mecamylamine to precipitate withdrawal. Rats were
then examined for physical signs of withdrawal and anxiety-like behavior. After testing, serum
levels of corticosterone, E2, and progesterone were assessed. Female rats received vaginal lavage
procedures to verify the phase of the estrous cycle on the test day. Results: Intact females displayed
greater anxiety-like behavior and higher corticosterone during withdrawal as compared to males
and OVX females. Intact females that were tested in estrus (when E2 levels are relatively low)
displayed less anxiety-like behavior and corticosterone as compared to all other phases. During
withdrawal, anxiety-like behavior and corticosterone were positively correlated with E2 and
negatively correlated with progesterone and the progesterone/E2 ratio. Intact females displaying
high E2/low progesterone levels displayed greater anxiety-like behavior and corticosterone as
compared to females displaying low E2/high progesterone levels. Lastly, OVX rats that received
E2 displayed greater anxiety-like behavior as compared to OVX rats that received vehicle. OVX
rats that received E2+progesterone displayed less anxiety-like behavior as compared to OVX rats
that received E2 alone. Conclusion: These data suggest that E2 promotes, whereas progesterone
reduces anxiety-like behavior produced by nicotine withdrawal.
v
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Chapter 1: Introduction
1.1 Tobacco use is a public health problem
Tobacco use is the leading cause of preventable deaths in the United States, with over
400,000 deaths per year attributed to smoking-related causes (U.S. Department of Health and
Human Services, 2014). Long-term tobacco use is associated with adverse health consequences
such as lung cancer, cardiovascular disease, and emphysema (D’Alessandro et al., 2012; Hecht,
2012; Milara and Cortijo, 2012). In addition to being a significant public health problem, tobacco
use is also an economic burden. Indeed, the costs associated with tobacco use exceeds more than
300 billion dollars each year (U.S. Department of Health and Human Services, 2016). Given the
magnitude of problems associated with tobacco use, more research is needed to understand the
mechanisms underlying smoking behavior.
1.2 Tobacco use is driven by nicotine reward and avoiding withdrawal
Studies have identified nonpharmacological factors that motivate tobacco use in humans
such as the need for appetite suppression, the desire to improve self-image, peer-pressure, and
anxiety management (Seguire & Chalmers 2000; Reid et al., 2009; Perkins et al., 1997;1999 &
2001). However, much work has also revealed that individuals use tobacco to experience the
psychopharmacological effects of nicotine, the main habit-forming compound in tobacco (U.S.
Department of Health and Human Services, 2014; Pogocki et al., 2007; Pontieri et al., 1996).
Current theories suggest that both positive and negative reinforcement processes motivate tobacco
use (George and Koob, 2017). For example, initial tobacco use is thought to be driven primarily
by nicotine acting as a positive reinforcer. Specifically, nicotine produces euphoria, increases
energy, and enhances attentional processes (Benowitz, 1996; Kaye et al., 2014; Pomerleau &
Pomerlaeau, 1992). Following chronic exposure, tobacco use is believed to be driven primarily via
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negative reinforcement involving the avoidance of negative affective states produced by nicotine
withdrawal (George and Koob, 2017; Pipkin et al., 2017). Indeed, abstinence from long-term
tobacco use leads to a withdrawal syndrome consisting of negative physical and affective states
that are alleviated by subsequent drug taking. The physical symptoms include nausea, headaches,
sleep disturbances, and an increase in food cravings (Hogle et al., 2006; Shiffman et al., 2004;
Hughes, 2007). The negative affective states produced by nicotine withdrawal include intense
craving, irritability, anxiety, depression, difficulty concentrating, as well as other forms of
cognitive impairments (Hughes et al., 1992; Pauly, 2008; Perkins et al., 2009; Hatsukami et al.,
1989 and Heishma et al., 1994). The emergence of physical and negative affective states during
abstinence are believed to promote continued tobacco use and relapse, as tobacco users will smoke
to avoid experiencing the symptoms of nicotine withdrawal (Baker et al., 2004; Battista et al.,
2008; Fidler et al., 2009; Hughes, 2007; Piper et al., 2011; Ríos-Bedoya et al., 2008).
1.3 Women are more vulnerable to tobacco use than men
Clinical reports suggest that women are more vulnerable to tobacco use than men.
Although men consume more tobacco products (Jamal et al., 2015), women are at higher risk of
developing tobacco-related diseases, including cancer and chronic obstructive pulmonary disease
(Kiyohara and Ono 2010; Langhammer et al., 2000). Women also exhibit lower smoking cessation
rates and are less likely to benefit from nicotine replacement therapy (NTR) than men (CepedaBenito et al., 2004; Perkins 2001; Perkins and Scott, 2008; Piper et al., 2010). Women also display
stronger negative affective states during abstinence than men (Panagiotakopoulos and Neigh,
2014; Perkins et al., 2012a, 2012b; Weinberger and McKee, 2012), and they report higher levels
of depression, anxiety, and intense craving during smoking abstinence as compared to men
(al’Absi, 2006; Schnoll et al., 2007; Xu et al., 2008; Leventhal et al., 2007; Pang et al., 2018).
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Consistent with the latter reports, women display higher levels of cortisol during smoking
abstinence than men (Hogle and Curtin, 2006). Not surprising, women report more often than men
that they smoke to avoid negative affective states produced by nicotine withdrawal (Stanton,
1995). These studies suggest that withdrawal from chronic tobacco use leads to higher levels of
anxiety and biological stress responses in women that likely promote higher rates of smoking
relapse in women as compared to men.
1.4 Ovarian hormones and tobacco use in women
A growing body of literature suggests that the ovarian hormones, estradiol (E2) and
progesterone modulate sex differences in the positive subjective effects of nicotine. One approach
to examine the relationship between ovarian hormones and the effects of drugs of abuse in women
is to examine responses to drugs of abuse across the different phases of the menstrual cycle (Anker
& Carrol, 2010). In women, the menstrual cycle is divided into two phases: the follicular stage,
where E2 levels are rising relative to progesterone, and the luteal phase where progesterone levels
are high relative to E2 (Owen, 1975). Women report greater subjective effects of nicotine in the
follicular versus the luteal phase of the menstrual cycle (DeVito et al., 2014). These findings are
consistent with work showing that women display greater positive subjective responses to cocaine
and amphetamine during the follicular as compared to the luteal phase of the menstrual cycle
(Evans and Foltin, 2006; Evans et al., 2002; Sofuoglu et al., 1999; Justice and de Wit, 1999). Given
the hormonal profile of the follicular (high E2) and luteal (high progesterone) phases, one might
expect that E2 promotes and progesterone attenuates the positive subjective effects of nicotine
(Sofuoglu et al., 2001, 2011).
Clinical reports also suggest that ovarian hormone fluctuations influence negative affective
states produced by nicotine withdrawal. Specifically, women who quit in the luteal phase of their
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menstrual cycle experience more withdrawal signs as compared to women that quit in the follicular
phase (O’Hara et al., 1989; Perkins et al., 2000). A meta-analytic review also revealed that women
reported greater withdrawal during the luteal versus follicular phase (Weinberger et al., 2015). It
is important to note that other reports have not found differences in the severity of the withdrawal
syndrome in women who quit during the follicular versus the luteal phase of the menstrual cycle
(Allen et al., 2000 & 2010). Although these studies suggest that ovarian hormones modulate
nicotine withdrawal in women, the relationship between withdrawal severity and E2 and
progesterone levels remains unclear. This question requires pre-clinical rodent studies that can
study nicotine withdrawal while manipulating ovarian hormones levels. Thus, this dissertation
examined the role of E2 and progesterone in a rodent model of nicotine withdrawal.
1.5 Female rat estrous cycle
In contrast to humans that display a 28-day menstrual cycle, female rats display a 4-5 day
estrous cycle. The rodent estrous cycle is similar to the human menstrual cycle that is tightly
regulated by circulating levels of E2 and progesterone, with receptors for these hormones in the
brain of both rats and humans (Schedin et al., 2000). The estrous cycle consists of 4 phases:
proestrus, estrus, metestrus, and diestrus. The proestrus stage is characterized by peak increases in
E2 and progesterone. The estrus stage is characterized by a steep decline in E2 and a gentle decline
in progesterone levels. The metestrus phase is characterized by stable low levels of E2 and a
gradual increase in progesterone. Lastly, the diestrus stage is characterized by stable low levels of
both E2 and progesterone (Butcher et al., 1974; Haim et al., 2003). The effects of ovarian hormones
on a given behavioral outcome can be examined following the removal of the ovaries and
subsequent E2 or progesterone supplementation.
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1.6 Sex differences in rodent models of nicotine withdrawal
In rodents, nicotine dependence can be induced via surgical implantation of an osmotic
pump that delivers nicotine for 7-14 days (Kenny and Markou, 2001; Malin, 2001; O’Dell et al.,
2004). Nicotine withdrawal can then be assessed following removal of the pump (spontaneous
withdrawal) or following administration of a nicotinic receptor antagonist, such as mecamylamine
(precipitated withdrawal). By either method, nicotine withdrawal produces a behavioral profile in
rodents that is comprised of physical signs and negative affective states. The physical signs of
nicotine withdrawal include facial fasciculations, teeth chatters, writhes, gasps, eye blinks, and
ptosis (Malin, 2001; O’Dell et al., 2004; Watkins et al., 2000). The negative affective states elicited
by withdrawal include anxiety-like behavior that can be assessed as an decrease in time spent in
the open arms of an elevated plus maze (EPM; Bruijnzeel et al., 2012; Tejeda et al., 2012;
Wilmouth and Spear, 2006) or the lit compartment of a light-dark transfer (LDT) apparatus (Stoker
et al., 2008) relative to control animals. This dissertation employs both EPM and LDT tests to
provide converging lines of evidence of anxiety-like behavior produced by withdrawal.
Previous studies have revealed that there are sex differences in the magnitude of negative
affective states produced by nicotine withdrawal in rodents. Specifically, females display a larger
aversion to an environment paired previously with nicotine withdrawal as compared to male rats
(O’Dell and Torres, 2014) and mice (Kota et al., 2007, 2008). Female rats also display higher
serum levels of corticosterone and adrenocorticotropic hormone during nicotine withdrawal as
compared to males (Gentile et al., 2011; Skwara et al., 2012). During nicotine withdrawal, female
rats also display higher levels of anxiety-like behavior and expression of stress-associated genes
in the nucleus accumbens (NAc) than males (Torres et al., 2013). These studies suggest that female
rats experience greater stress during nicotine withdrawal as compared to males. Previous work has
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also revealed that OVX rats display reduced negative affective states during nicotine withdrawal
as compared to intact female rats (Torres et al., 2015). OVX rats also display a reduction in
corticosterone levels and decreased expression of stress-associated genes in the NAc relative to
intact females (Torres et al., 2015). Previous work has also revealed that OVX females display less
nicotine intravenous self-administration as compared to intact females, an effect that was reversed
in OVX females that received E2 supplementation (Flores et al., 2016). Taken together, these
studies suggest that the behavioral effects of nicotine are ovarian hormone-dependent. However,
the specific role of E2 and progesterone in promoting nicotine withdrawal have not been examined.
1.7 Critical knowledge gap this dissertation addresses
Clinical evidence suggests that the stress produced by nicotine withdrawal drives smoking
behavior and relapse during nicotine withdrawal. However, there is a lack of pre-clinical studies
examining sex differences in the stress response produced by withdrawal. Furthermore, the role of
E2 and progesterone in promoting stress during withdrawal remains unclear. This dissertation
addressed these issues by examining behavioral and biological indices of stress produced by
nicotine withdrawal in rats. Aim 1 characterized sex differences and the role of ovarian hormones
in nicotine withdrawal. This was achieved by assessing nicotine withdrawal in male, intact female,
and OVX rats. Next, the magnitude of withdrawal was compared in intact females tested in
proestrus, estrus, metestrus, and diestrus. Lastly, the relationship between withdrawal and levels
of E2 and progesterone were assessed in intact females. Aim 2 validated the role of ovarian
hormones in nicotine withdrawal. This was achieved by examining whether ovarian hormone
replacement influenced the expression of nicotine withdrawal in OVX rats that received vehicle,
E2, or E2+progesterone supplementation.
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Chapter 2: Methods
2.1 Subjects
Male and female Wistar rats were obtained from an out-bred stock of animals (Envigo,
Inc., Indianapolis, IN). On post-natal day (PND) 21, the rat pups were weaned and housed with a
same-sex littermate for the remainder of the study. The rats were housed in a humidity- and
temperature-controlled (22◦C) vivarium on a reverse 12-hour light/dark cycle (lights off at 8:00
am and on at 8:00 pm) and ad libitum access to food and water. Prior to beginning the experiment,
the rats were handled for 5 days. All the experimental procedures were approved by the UTEP
Institutional Animal Care and Use Committee.
2.2 Overall design

These diagrams depict our experimental groups and procedures. Aim 1 compared sex
differences and the role of ovarian hormones in the behavioral effects of nicotine withdrawal.
Nicotine-dependent male, intact female, and OVX female rats received saline or mecamylamine
(1.5 or 3.0 mg/kg) to precipitate withdrawal on the test day. Aim 2 examined the role of E2 and
7

E2+progesterone in the behavioral effects of nicotine withdrawal. Nicotine-dependent OVX
females were supplemented with vehicle, E2, or E2+progesterone, and they received saline or
mecamylamine (3.0 mg/kg) on the test day. Only the highest dose of mecamylamine was included
because sex differences in nicotine withdrawal were observed at this dose and robust withdrawal
effects were only detected at this high dose in OVX females in Aim 1. The rats received either a
surgical sham or OVX procedure. Fifteen days later, rats were prepared with an osmotic pump that
delivered nicotine continuously. Following 14 days of nicotine exposure, the rats received
mecamylamine to precipitate withdrawal and they were tested in a series of behavioral tests that
included the physical signs and two tests of anxiety-like behavior, the EPM and LDT procedures.
At the end of testing in Aim 1, trunk blood was collected to assess serum E2 and progesterone
levels. Also, the intact females received vaginal lavage procedures to assess the phase of the
estrous cycle that they were tested in. After behavioral testing in each study, trunk blood was
collected to assess serum corticosterone levels in all groups.
2.3 Surgery
At PND 45-46, the rats were anesthetized using an isoflurane/oxygen mixture (1-3%
isoflurane). Some of the female rats received surgical removal of ovarian tissue, as previously
described (Torres et al., 2009). In order to control for any behavioral disruptions produced by
surgery, male and intact female rats received a sham procedure consisting of anesthesia and then
an incision in the same location as the OVX procedure. The OVX was done at PND 45-46 based
on previous work in our laboratory showing that female rats that received OVX procedures at PND
45 display a reduction in the rewarding effects of nicotine (Torres et al., 2009; Flores et al., 2016)
and a suppression of anxiety-like behavior and stress-associated gene expression during nicotine
withdrawal (Torres et al., 2013, 2015). These studies suggest that after PND 45, ovarian hormones
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play a key role in modulating the behavioral effects of nicotine withdrawal. Once the rats reached
PND 60, the rats were re-anesthetized and then surgically prepared with an osmotic pump that
delivered nicotine continuously for 14 days (3.2 mg/kg/day, expressed as base; model 2ML2; 5.0
ul/hour; Durect Corporation, Inc.). Previous studies in our laboratory have shown that this dose of
nicotine produces similar levels of cotinine (a major nicotine metabolite) in male and female rats
(O’Dell et al., 2007).
2.4 Behavioral testing
The rats were removed from the vivarium and placed into a clear Plexiglas® cage in a test
room that was dedicated to the assessments of physical signs of withdrawal under regular light
conditions. Following a 10-min acclimation period, the rats received an injection of saline or
mecamylamine (1.5 or 3.0 mg/kg), and 10 min later the physical signs of withdrawal were
assessed. The observed signs included blinks, writhes, body shakes, teeth chatters, gasps,
grooming bouts, licks, and ptosis. Multiple successive counts of any sign required a distinct pause
between episodes. Ptosis was only counted once per min. The total number of somatic signs were
defined as the sum of individual occurrences of the signs during the entire observation period.
Following the physical signs assessment, the rats were placed in a transport cage and acclimated
to another dimly lit room for 5 min prior to testing in the EPM. The EPM apparatus consists of 4
arms elevated to a height of 50 cm above the ground. The apparatus was illuminated by a red light
suspended from the ceiling of a dark room. At the beginning of the test, the rats were placed in the
center of the EPM facing an open arm. Time spent in the center area, open, and closed arms were
recorded for 5 min. Anxiety-like behavior was operationally defined as a decrease in time spent in
the open arms relative to control rats. Following EPM testing, the rats were returned to their
transport cage and acclimated for 5 min to a separate room dedicated to the LDT test. The LDT
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apparatus consists of 2 chambers, one side consists of clear Plexiglas® and the other side is
enclosed and painted solid black. The apparatus is separated by a wall with an opening that allowed
the rats to pass between the 2 sides freely. The apparatus was positioned in the middle of the room
under regular light conditions. At the start of the test, the rats were placed in the middle of the dark
chamber facing the back wall of the apparatus. The time spent in each side was scored for 5 min.
Anxiety-like behavior test was operationally defined as a decrease in time spent in the lit
compartment relative to control rats. The test equipment was thoroughly cleaned and dried before
each rat was tested.
2.5 Hormone level assessments
After behavioral testing, the intact female rats in Aim 1 were sacrificed, and trunk blood
was collected. The blood was centrifuged for 15 min at 5000 x g at 4°C. Serum was extracted and
stored in 100 ul aliquots at -80°C until analyzed via enzyme-linked immunosorbent assay (ELISA)
procedures for progesterone (Enzo Life Sciences, Farmingdale, USA) and corticosterone
(Assaypro, Winfield, MO) according to the manufacturer instructions. The standards ranged from
0 to 100 ng/mL for corticosterone and 0 to 500 pg/mL for progesterone, and they were included in
every assay. Samples were placed in a 96 well-plate and read at 450 and 630 nm wavelength using
a Spectra Maxplus spectrophotometer (Molecular Devices, Inc.). E2 levels were assayed at the
University of Pittsburgh Small Molecule Biomarker Core, using liquid chromatography-tandem
mass spectrometry (LC-MS/MS). LC-MS/MS is the preferred method to estimate serum E2 levels
given that the serum concentration of this hormone is below a detectable range of sensitivity for
standard immunoassays, such as ELISA.
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2.6 Estrous cycle determination
Vaginal lavage procedures were used to estimate the phase of the estrous cycle (i.e.,
proestrus, estrus, metestrus, or diestrus). In Aim 1, the lavage procedures began 8 days prior to the
pump surgery and continued until the end of the final test day. As a control procedure, the male
rats were handled every day. In Aim 2, OVX females only received lavage procedures on the final
test day. A sterile and disposable plastic pipette was filled with 0.9% saline and was used to collect
epithelial cells. Epithelial cells were then transferred to a labeled glass microscope slide.
Microscope slides were fixed with methylene blue stain (Sigma, Inc.) and viewed under a light
microscope at 40X to examine the shape of the cells and determine the phase of the estrous cycle
by the following criteria: proestrus=presence of round nucleated epithelium cells, estrus=presence
of cornified un-nucleated epithelium cells, metestrus=limited presence of epithelium cell and
leukocytes and diestrus=presence of leukocytes (Goldman et al 2007).
2.7 Hormone supplementation procedures
In Aim 2, OVX females received a 4-day E2 supplementation procedure that began the
following day after ovariectomy surgery. OVX controls received repeated vehicle injections
(peanut oil). To examine the effects of E2 alone, a group of OVX females received 2 days of a 0.1
mL bolus injection of E2 (5 µg), 1 day of vehicle injection, and no injection on the final day of the
4-day cycle. This supplementation procedure mimics normal E2 cycling patterns in intact female
rats (see Asarian et al., 2002). On the test day, the rats received their E2 injection 30 min prior to
the beginning of the behavioral battery. To examine the effects of E2 and progesterone, a group of
OVX females received 2 days of a 0.1 mL bolus injection of E2 (5 µg), 1 day of progesterone (250
µg), and no injection on the final day of the 4-day cycle. On the test day, rats received progesterone
4.5 hours prior to the beginning of the behavioral battery. The 4-day supplementation procedures
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were repeated 5 times prior to testing. A group that received progesterone alone was not included
because progesterone only induces sexual receptivity in OVX rats that are supplemented with
E2+progesterone (Becker et al., 2005).
2.8 Statistics
In Aim 1, the data were analyzed separately for each measure (physical signs, EPM, LDT,
and corticosterone) using 2-way ANOVAs with group (male, female, and OVX) and treatment
condition (0, 1.5, and 3.0 mg/kg of mecamylamine) as between subject factors. Across all
measures, significant interaction effects were further analyzed using post-hoc comparisons where
appropriate. To examine estrous cycle effects, the female rats that received the 3.0 mg/kg dose of
mecamylamine were grouped according to the stage of estrous they were tested in. The data were
then analyzed separately for each measure (physical signs, EPM, LDT, and corticosterone) using
a 1-way ANOVA with stage of estrous (proestrus, estrus, metestrus and diestrus) as a between
subjects factor. The relationship between hormones and the behavioral effects of withdrawal was
examined via simple linear regression. Each hormone was correlated separately and as a ratio of
progesterone to E2 with each measure of nicotine withdrawal. The ratio of these hormones was
compared based on prior work showing that influence of ovarian hormones on nicotine IVSA is
most evident when E2 and progesterone levels are expressed in relative proportion to each other
(see Lynch, 2009). The measures of nicotine withdrawal were then regressed on the
progesterone/E2 ratios and the Pearson correlation co-efficient was computed to assess the strength
and direction of each relationship. A one-sample t-test was used to examine whether the
correlations were statistically significant. In intact female rats, the relative concentration of E2 and
progesterone varies during each phase of the estrous cycle. We used statistical approaches to assess
whether intact females could be categorized into groups that displayed similar concentrations of

12

these hormones. A k-means clustering algorithm was used to classify rats according to their levels
of E2 and progesterone. This analysis resulted in 2 groups that had significantly different hormone
levels (high E2/low progesterone and low E2/high progesterone). Individual rats were grouped
according to their group membership and differences in each measure (physical signs, EPM, LDT,
and corticosterone) were compared using a between-subjects t-test. This k-means categorization
process has been used to classify older and younger animals according to their performance in
working memory and behavioral flexibility tasks (Mota et al., 2019). In Aim 2, the data were
analyzed separately for each measure (physical signs, EPM, LDT, and corticosterone) using 2-way
ANOVA with group (OVX-VEH, OVX-E2, OVX-E2+progesterone) and treatment (0 or 3.0
mg/kg of mecamylamine) as between subject factors. Significant interaction effects were further
analyzed using post-hoc comparisons where appropriate.
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Chapter 3: Results
3.1 Aim 1
Figure 1 displays physical signs (A), EPM (B), LDT (C), and corticosterone levels (D) in
nicotine-treated male, intact female, and OVX rats that received mecamylamine (0, 1.5, or 3.0
mg/kg) on the test day. With regard to physical signs, there were no interaction effects between
group and treatment conditions [F(4,154)=0.57; p=0.58]. However, there was a main effect of
treatment condition [F(2,154)=98.33; p<0.05], with rats that received the 1.5 or 3.0 mg/kg dose
of mecamylamine displaying more physical signs as compared to saline controls (*p<0.05).
With regard to the EPM data, a 2-way ANOVA of percent time in open arms revealed a
significant interaction between group and treatment condition [F(4,154)= 2.87; p<0.05]. In males,
post-hoc analyses revealed a significant decrease in % time in open arms in rats that received the
1.5 or 3.0 mg/kg dose of mecamylamine as compared to saline controls (*p<0.05). There was no
difference between males that received the 1.5 or 3.0 mg/kg dose of mecamylamine (p=0.47). In
intact females, post-hoc analyses revealed a significant decrease in % time in open arms in rats
that received the 1.5 or 3.0 mg/kg dose of mecamylamine as compared to saline controls (*p<0.05).
The % time in open arms was lower in intact females that received the 3.0 versus 1.5 mg/kg dose
of mecamylamine (#p<0.05). In OVX females, post-hoc analyses revealed a significant decrease
in % time in open arms in rats that received the 1.5 or 3.0 mg/kg dose of mecamylamine as
compared to their respective saline controls (*p<0.05). There was no difference between OVX rats
that received the 1.5 versus 3.0 mg/kg dose of mecamylamine (*p=0.59). Group differences were
detected in rats that were treated with the 3.0 mg/kg dose of mecamylamine. Post-hoc analyses
revealed that % time in open arms was lower in intact females as compared to male and OVX rats
(†p<0.05).
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With regard to the LDT data, a 2-way ANOVA of percent time the lit compartment
revealed a significant interaction between group and treatment condition [F(4,154)=3.02; p<0.05].
In males, post-hoc analyses revealed a significant decrease in % time in the lit compartment in rats
that received the 3.0 (*p<0.05), but not the 1.5 (p=0.06) mg/kg dose of mecamylamine as
compared to saline controls. There was no difference between males that received the 1.5 or 3.0
mg/kg dose of mecamylamine (p=0.25). In intact females, post-hoc analyses revealed a significant
decrease in % time in the lit compartment in rats that received the 1.5 or 3.0 mg/kg dose of
mecamylamine as compared to female saline controls (*p<0.05). The % time in the lit
compartment was lower in intact females that received the 3.0 versus 1.5 dose mg/kg of
mecamylamine (#p<0.05). In OVX females, post-hoc analyses revealed a significant decrease in
% time in the lit compartment in rats that received the 3.0 (*p<0.05), but not the 1.5 (p=0.28)
mg/kg dose of mecamylamine as compared to OVX saline controls. The % time in the lit
compartment was lower in OVX females that received the 3.0 versus 1.5 mg/kg dose of
mecamylamine (#p<0.05). Group differences were detected in rats that were treated with the 1.5
mg/kg dose of mecamylamine. Post-hoc analyses revealed that % time in the lit compartment was
lower in intact females as compared to OVX rats (@p<0.05). Group differences were also detected
in rats that were treated with the 3.0 mg/kg dose of mecamylamine. Post-hoc analyses revealed
that % time in the lit compartment was lower in intact females as compared to male and OVX rats
(†p<0.05).
With regard to corticosterone levels, a 2-way ANOVA revealed a significant interaction
between group and treatment condition [F(4,154)=2.60; p<0.05]. In males, post-hoc analyses
revealed a significant decrease in % time in the lit compartment in rats that received the 1.5 or 3.0
mg/kg dose of mecamylamine as compared to saline controls (*p<0.05). There was no difference
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between males that received the 1.5 or 3.0 mg/kg dose of mecamylamine (p=0.18). In intact
females, post-hoc analyses revealed a significant increase in corticosterone in rats that were treated
with the 1.5 or 3.0 mg/kg dose of mecamylamine as compared to saline controls (*p<0.05).
Corticosterone was also higher in intact females that received the 3.0 versus 1.5 mg/kg dose of
mecamylamine (p<0.05). In OVX females, post-hoc analyses revealed a significant increase in
corticosterone in rats that were treated with the 3.0 (*p<0.05), but not the 1.5 (p=0.59) mg/kg dose
of mecamylamine as compared to saline controls. Corticosterone did not differ in OVX rats that
received the 1.5 versus the 3.0 mg/kg dose of mecamylamine (p=0.34). Group differences were
detected across rats that were treated with the 1.5 mg/kg dose of mecamylamine. Post-hoc analyses
revealed that corticosterone was higher in intact females as compared to OVX (@p<0.05), but not
male rats (p=0.41). Group differences were detected across rats that were treated with the 3.0
mg/kg dose of mecamylamine. Post-hoc analyses revealed that corticosterone was higher in intact
females as compared to both male and OVX rats (†p<0.05).
Figure 2 displays E2 (A) and progesterone (B) levels in intact nicotine-treated females that
received mecamylamine (3.0 mg/kg) and were tested during various phases of the estrous cycle.
With regard to E2, a 1-way ANOVA revealed a significant interaction between group and
treatment condition [F(3,34)=3.63; p<0.05]. Post-hoc analyses revealed that females tested in
estrus displayed lower E2 as compared to rats that were tested in all of the other phases combined
(†p<0.05). With regard to progesterone, a 1-way ANOVA revealed a significant interaction
between group and treatment condition [F(3,34)=12.20; p<0.05]. Post-hoc analyses revealed that
females tested in estrus displayed higher progesterone levels as compared to rats that were tested
in all of the other phases combined (†p<0.05).

16

Figure 3 displays physical signs (A), EPM (B), LDT (C), and corticosterone levels (D) in
intact nicotine-treated females that received mecamylamine (3.0 mg/kg) and were tested during
various phases of the estrous cycle. With regard to physical signs, a 1-way ANOVA revealed that
there were no main effects of estrous cycle [F(3, 34) = 0.42; p=0.74].With regard to the EPM data,
a 1-way ANOVA of % time in open arms revealed a main effect of estrous cycle [F(3, 34)=4.96;
p<0.05]. Post-hoc analyses revealed that females that were tested in estrus displayed greater %
time in the open arms as compared to females (†) that were tested in proestrus, metestrus, and
diestrus (†p<0.05). With regard to the LDT data, a 1-way ANOVA of % time in the lit
compartment revealed a main effect of estrous cycle [F(3, 34)=3.14; p<0.05]. Post-hoc analyses
revealed that females tested in estrus displayed greater % time in the lit compartment as compared
to females in proestrus, metestrus, and diestrus (†p<0.05). With regard to corticosterone, a 1-way
ANOVA revealed a main effect of estrous cycle [F(3, 34)=3.11; p<0.05]. Post-hoc analyses
revealed that females that were tested in estrus displayed lower corticosterone as compared to all
other phases combined (†p<0.05).
Table 1 displays correlation values (Pearson’s r) between behavioral measures of
withdrawal or corticosterone with ovarian hormone levels (E2, progesterone, and progesterone/E2
ratios). With regard E2, there was no correlation between E2 and physical signs of withdrawal
(r=0.29, p=0.07). However, there was a significant negative correlation between E2 and % time in
open arms of the EPM (r=-0.38; p<0.05). There was a negative correlation between E2 and % time
in the lit compartment of the LDT (r=-0.32; p<0.05). There was a positive correlation between E2
and corticosterone (r=0.35; p<0.05). With regard to progesterone, there was no correlation between
progesterone and physical signs of withdrawal (r=-0.16; p=0.35). There was a positive correlation
between progesterone and % time in open arms of the EPM (r=0.44; p<0.05); however, there was
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no correlation between progesterone and % time in the lit compartment of the LDT (r=0.22;
p=0.26). There was a negative correlation between progesterone and corticosterone (r=-0.43;
p<0.05). With regard to the progesterone/E2 ratios, there was a negative correlation between
progesterone/E2 and physical signs of withdrawal (r=-0.36; p<0.05). There was a positive
correlation between progesterone/E2 and % time in open arms of the EPM (r=0.36; p<0.05).
However, there was no correlation between progesterone/E2 and in % time in the lit compartment
of the LDT (r=0.18; p=0.26). Lastly, we observed a negative correlation between progesterone/E2
and corticosterone (r=-0.36; p<0.05).
Figure 4 reflects E2 and progesterone levels in the 2 groups of intact females that were
derived from the cluster analysis. This statistical method partitions individual observations into
clusters with the nearest mean value. Although this approach can result in any number of clusters,
the analysis of our data revealed 2 groups of intact females that displayed high E2/low
progesterone or low E2/high progesterone levels. In order to assess whether these clusters are
statistically different from each other, we compared E2 and progesterone between these 2 groups.
With regard to E2, an independent-samples t-test revealed a significant difference between the
high E2/low progesterone versus the low E2/high progesterone group (t(36)=3.17, p<0.05). With
regard to progesterone, there was a significant difference between the low E2/high progesterone
versus the high E2/low progesterone group (t(36)=16.2, p<0.05).
Figure 5 displays physical signs (A), EPM (B), LDT (C), and corticosterone levels (D)
following administration of mecamylamine (3.0 mg/kg) in nicotine-dependent females that
displayed either high E2/low progesterone or low E2/high progesterone. With regard to physical
signs, there were no differences in physical signs between the high E2/low progesterone versus
low E2/high progesterone groups (t(36)=1.14, p=0.26). With regard to the EPM data, females that
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displayed high E2/low progesterone displayed less % time in the open arms of the EPM as
compared to females that displayed low E2/high progesterone (t(36)=3.50; p<0.05). With regard
to the LDT data, females displaying high E2/low progesterone spent less time in the lit
compartment as compared to females that displayed low E2/high progesterone (t(36)=3.24,
p<0.05). With regard to corticosterone, females displaying high E2/low progesterone had higher
corticosterone as compared to females that displayed low E2/high progesterone (t(36)=2.12,
p<0.05).
3.2 Aim 2
Figure 6 displays physical signs (A), EPM (B), LDT (C), and corticosterone levels (D) in
nicotine-treated OVX females that were supplemented with vehicle (OVX-vehicle), E2 (OVXE2), or both E2 and progesterone (OVX-E2+progesterone) and received mecamylamine (0 or 3.0
mg/kg) on the test day. With regard to physical signs, there were no interaction effects between
group and treatment condition [F(2,61)=1.96; p=0.15]. However, there was a main effect of
treatment condition [F(1,61)=441.95; p<0.05], with rats that received the 3.0 mg/kg dose of
mecamylamine displaying more physical signs as compared to saline controls (*p<0.05). There
were no differences in withdrawal signs across OVX-vehicle, OVX-E2, or OVX-E2+progesterone
groups.
With regard to the EPM data, a 2-way ANOVA revealed a significant interaction between
group and treatment condition [F(2,61)=3.70; p<0.05]. Post-hoc analyses revealed that % time in
open arms was lower in rats that received the 3.0 mg/kg dose of mecamylamine as compared to
saline controls, an effect that was significant in OVX-vehicle, OVX-E2, and OVXE2+progesterone rats (*p<0.05). Group differences were detected in OVX rats that received the
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3.0 mg/kg dose of mecamylamine. Post-hoc analyses revealed that % time in open arms was lower
in OVX-E2 rats as compared to OVX-vehicle and OVX-E2+progesterone (†p<0.05) rats.
With regard to the LDT data, a 2-way ANOVA revealed a significant interaction between
group and treatment condition [F(2,61)=4.82; p<0.05]. Post-hoc analyses revealed a significant
decrease in % time in the lit compartment in rats that received the 3.0 mg/kg dose of
mecamylamine as compared to saline controls, an effect that was significant in OVX-vehicle,
OVX-E2, and OVX-E2+progesterone rats (*p<0.05). Group differences were detected in rats that
received the 3.0 mg/kg dose of mecamylamine. Post-hoc analyses revealed that % time in the lit
compartment was lower in OVX-E2 rats as compared to OVX-vehicle and OVX-E2+progesterone
rats (†p<0.05).
With regard to corticosterone, a 2-way ANOVA revealed that there were no interaction
effects between group and treatment condition [F(2, 61)=0.91; p=0.12]. However, there was a main
effect of treatment condition [F(1,61)=15.56; p<0.05], with rats that received the 3.0 mg/kg dose
of mecamylamine displaying higher corticosterone as compared to saline controls (*p<0.05). Also,
there was a main effect of group [F(1,61)=20.80; p<0.05]. Post-hoc analyses revealed that
regardless of treatment condition, OVX-E2+progesterone rats displayed higher corticosterone
levels than OVX-vehicle and OVX-E2 rats (#p<0.05).
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Chapter 4: Discussion
4.1 Summary
The major finding is that intact female rats displayed greater indices of stress produced by
nicotine withdrawal as compared to males, an effect that was ovarian hormone-dependent.
Specifically, intact females displayed greater anxiety-like behavior and higher corticosterone
levels during withdrawal as compared to males and OVX females. With regard to differences in
nicotine withdrawal across the estrous cycle, intact females that were tested in estrus (when E2
levels are relatively low) displayed less anxiety-like behavior and corticosterone as compared to
all other phases. In intact females, the magnitude of anxiety-like behavior and corticosterone levels
during withdrawal were positively correlated with E2 and negatively correlated with progesterone
and the progesterone/E2 ratio. In an assessment of E2 and progesterone levels in intact females, 2
clusters emerged displaying either high E2/low progesterone or low E2/high progesterone.
Females displaying high E2/low progesterone levels showed greater anxiety-like behavior and
corticosterone during withdrawal as compared to females displaying low E2/high progesterone.
Lastly, OVX rats that received E2 supplementation displayed greater anxiety-like behavior as
compared to OVX rats that received vehicle. OVX rats that received E2+ progesterone
supplementation did not differ in anxiety-like behavior as compared to OVX rats that received
vehicle. All groups of OVX rats displayed an increase in corticosterone levels regardless of
treatment condition.
4.2 Is nicotine withdrawal sex- and ovarian hormone-dependent?
With regard to sex differences in nicotine withdrawal, intact females displayed similar
levels of physical signs as compared to males, consistent with previous studies from our laboratory
(Torres et al., 2013; Correa et al., 2019) and others using similar experimental conditions
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(Hamilton et al., 2009). However, we acknowledge that the latter report also found that male rats
display more physical signs of withdrawal in a dimly lit test room, suggesting that sex differences
in the magnitude of the physical signs of withdrawal may differ depending on the lighting
conditions of the test room. During nicotine withdrawal, we also observed that intact females
displayed greater anxiety-like behavior and corticosterone levels as compared to males.
Specifically, intact females displayed less time in the open arms of the EPM and the lit
compartment of the LDT box, and higher corticosterone levels as compared to males. These
findings are consistent with previous work in our laboratory showing that during nicotine
withdrawal, female rats display higher levels of anxiety-like behavior (Torres et al., 2013). Reports
from other laboratories have also revealed that female rats display higher serum levels of
corticosterone and adrenocorticotropic hormone during nicotine withdrawal as compared to males
(Gentile et al., 2011; Skwara et al., 2012). The notion that female rodents experience greater
negative affective states during withdrawal is consistent with the finding that both female rats and
mice display a greater aversion to an environment paired previously with nicotine withdrawal
(Kota et al., 2007, 2008; O’Dell and Torres, 2014).
With regard to the role of ovarian hormones in nicotine withdrawal, OVX females
displayed similar physical signs as compared to intact females. Interestingly, OVX females
displayed less anxiety-like behavior than intact females, consistent with previous work in our
laboratory (Torres et al., 2015). This suggests that ovarian hormones play an important role in
modulating strong stress responses (but not physical signs) produced by nicotine withdrawal in
female rats. The different pattern of results in OVX rats suggests that physical signs and negative
affective states produced by withdrawal are modulated via distinct brain mechanisms, a suggestion
that has been put forth in recent review papers (Malin et al., 2017; Molas et al., 2017).
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4.3 Is the magnitude of nicotine withdrawal estrous cycle-dependent?
In the present study, the physical signs of withdrawal were similar across the 4 phases of
the estrous cycle, a finding that is not consistent with a recent report showing that physical signs
are higher in metestrus versus proestrus female rats (Henceroth et al., 2018). The present study
also found that estrus females displayed less anxiety-like behavior and corticosterone levels as
compared to all other phases. Specifically, estrus females spent more time in the open arms of the
EPM and the lit compartment of the LDT box and displayed lower corticosterone levels as
compared to all other phases. Following chronic social stress, one report revealed that estrus
female rats display less anxiety-like behavior in the EPM as compared to diestrus females
(McCormick et al., 2008). Shansky et al., (2004) also found that estrus females displayed less
impairments on a learning task following a pharmacological stressor as compared to proestrus
females. Also, other studies found that corticosterone levels were lower in estrus females following
presentation of an acute stressor as compared to proestrus females (Viau and Meaney 1991; Conrad
et al., 2004). Baseline levels of anxiety-like behavior have also been shown to be lower in estrus
versus diestrus females (Frye & Rhodes et al., 2006; Gouveia et al., 2004; Marcondes et al., 2001;
Mora et al., 1996). Also, corticosterone release is lower in estrus versus proestrus females
following acute restraint stress (Figueiredo et al., 2002). Together, these studies suggest that stress
responses may be lower during the estrus phase, perhaps because this is a fertile phase of the cycle
that is also characterized by greater exploratory behaviors that promote mating behavior (Frye and
Rhodes et al.,2006; McCormick et al., 2008). The present study also revealed that estrus females
displayed lower E2 and higher progesterone levels as compared to all other phases. These findings
suggest that the magnitude of nicotine withdrawal may be greater during phases of the cycle when
E2 is lower and progesterone is higher relative to the other phases of the estrous cycle.

23

4.4 Is the magnitude of nicotine withdrawal related to E2 and progesterone levels?
The present study correlated each intact female rat’s hormone levels with 4 different
outcomes (physical signs, EPM, LDT, and corticosterone). E2 and progesterone levels did not
appear to be correlated with physical signs produced by withdrawal. Anxiety-like behavior and
corticosterone levels were positivity correlated with E2 and negatively correlated with
progesterone levels. This effect was not observed in our measures of anxiety-like behavior on the
LDT, an effect that may be related to fluctuating hormone levels across individual rats. Indeed, the
cluster analysis allowed us to compare our measures of withdrawal in groups of animals that were
categorized by high E2/low progesterone or low E2/high progesterone. Indeed, our analysis of
these groups revealed that rats displaying high E2/low progesterone displayed greater anxiety-like
behavior in both the EPM and LDT tests. These findings suggest that E2 promotes and
progesterone reduces the magnitude of anxiety-like behavior and corticosterone levels during
nicotine withdrawal. To our knowledge, the present study is the first assessment of the relationship
between ovarian hormone levels and the magnitude of nicotine withdrawal in rodents.
4.5 What are the effects of hormone supplementation on nicotine withdrawal in OVX rats?
In the present study, the physical signs of withdrawal were similar in OVX rats that
received vehicle, E2, or E2+progesterone supplementation. These data further support our
assertion that ovarian hormones do not play a role in physical signs produced by nicotine
withdrawal. Interestingly, the data also revealed that OVX rats that received E2 supplementation
displayed higher levels of anxiety-like behavior as compared to OVX rats that received vehicle.
Specifically, during nicotine withdrawal, OVX-E2 rats spent less time in the open arms of the EPM
and the lit compartment of the LDT box as compared to OVX-vehicle rats. This finding is
consistent with our assertion from Aim 1 that E2 promotes anxiety-like behavior produced by
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nicotine withdrawal. The cytology of the OVX-E2 rats revealed that these animals were tested in
a proestrus-like phase. This is of interest given that high levels of anxiety-like behavior were
observed in the proestrus rats of Aim 1 and the OVX-E2 animals of Aim 2. The results revealed
that OVX-E2+progesterone rats displayed less anxiety-like behavior as compared to the OVX-E2
rats. This might have been related to the direct anxiolytic effects of progesterone given that this
hormone was administered 4.5 hour prior to the test. Also, the cytology of the OVXE2+progesterone rats revealed that these animals were tested in an estrus-like phase. The lower
levels of anxiety-like behavior in this group is consistent with the estrus females in Aim 1. Thus,
our ovarian supplementation procedures in Aim 2 induced cytology patterns and behavioral
outcomes that mimicked the pattern of results in intact females that were tested in estrus and
proestrus in Aim 1.
4.6 Major conclusions and significance
The major conclusion of this dissertation is that E2 increases anxiety-like behavior during
nicotine withdrawal in females. This assertion is based on our finding that anxiety-like behavior
was lowest in the intact females that were tested in the estrus phase, when E2 levels are the lowest
(Bohler., et al., 1990; Nappi et al., 1997). In our assessment of ovarian hormone levels, we also
found that estrus females displayed lower levels of E2 as compared to rats tested in all other phases
of the estrous cycle. Also, in intact females, E2 levels were positively correlated with anxiety-like
behavior during nicotine withdrawal. Lastly, OVX rats that received E2 supplementation also
displayed higher anxiety-like behavior as compared to OVX rats that received vehicle. This finding
is consistent with a previous report showing that OVX rats that received E2 supplementation
displayed greater sensitivity to pharmacological stressor as compared to OVX rats that received
vehicle (Shansky et al., 2004). The ability of E2 to increase sensitivity to a stressful stimulus in
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females may be due to the direct effects of E2 on the hypothalamus pituitary adrenal (HPA) axis.
This is based on our finding that OVX rats displayed reduced basal corticosterone levels and this
is reversed following E2 replacement. Also, previous work revealed that the increase in
corticosterone levels produced by acute stress are greater in OVX rats that received E2
supplementation (Handa & Weiser, 2014; Green et al., 2018). Also, the highest levels of the stress
hormone, corticotropin releasing factor (CRF) were observed during proestrus, when E2 levels are
highest (Bohler et al., 1990; Nappi et al., 1997). The present finding suggests that E2 promotes
anxiety-like behavior produced by nicotine withdrawal in females.
Another conclusion of the present study is that progesterone appears to decrease anxietylike behavior produced by nicotine withdrawal in females. This assertion is based on our finding
that intact female rats displaying high levels of progesterone display less anxiety-like behavior and
corticosterone release relative to intact females displaying lower levels of progesterone. Also, our
OVX rats that received E2+progesterone displayed less anxiety-like behavior as compared to OVX
rats that received E2 alone, suggesting that progesterone may have reduced the intense anxiety
observed in the OVX+E2 rats during withdrawal. Previous work has shown that progesterone
administration decreases anxiety-like behavior in intact and OVX mice (Mora et al., 1996; Reddy
et al., 2005). These data suggest that progesterone decreases anxiety-like behavior produced by
nicotine withdrawal in females.
The work in this dissertation is significant because it reflects an important first step towards
understanding the role of ovarian hormones modulate tobacco use in females. This dissertation
revealed that E2 promotes anxiety-like behavior, whereas progesterone reduces stress produced by
nicotine withdrawal. The results of this study might inform the development of more effective
tobacco cessation strategies in females. For example, one might expect a medical professional to
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assess the hormone status of a women who is contemplating quitting smoking. Our data suggest
that the best time to quit smoking may be in phases of the cycle when E2 levels are lowest and
progesterone levels are relatively higher in order to minimize the extent to which E2 may intensify
the nicotine withdrawal syndrome. Indeed, a clinical report revealed that women have an easier
time quitting smoking during the luteal phase, when E2 levels are decreasing and progesterone
levels are relatively higher (Allen et al., 2008). Future studies are need to more fully understand
the underlying biological factors that modulate the aversive effects nicotine withdrawal and
promote tobacco use in females. This work will be an essential step towards developing more
effective cessation strategies that will reduce health disparities produced by tobacco use in women.
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Table 1. Correlation values (Pearson’s r) between behavioral measures of
nicotine withdrawal or corticosterone levels with ovarian hormone levels
Measure
E2
Progesterone Progesterone/E2
ratio
0.30
-0.16
-0.36*
Physical signs
Anxiety − like behavior
EPM
LDT
Corticosterone

-0.40*
-0.32
0.35*

0.44*
0.23
-0.44*

0.35*
0.18
-0.37*

* Reflects a significant correlation (p ≤ 0.05).

Table 1. Correlations between measures of nicotine withdrawal and E2, progesterone, or
progesterone/E2 ratios in intact females that received the 3.0 mg/kg dose of mecamylamine. There
was a negative correlation between physical signs and the progesterone/E2 ratio. There was a
negative correlation between anxiety-like behavior on the EPM and E2. There was a positive
correlation between corticosterone and E2. There was a positive correlation between anxiety-like
behavior on the EPM and progesterone and the progesterone/E2 ratio. There was a negative
correlation between corticosterone and progesterone and the progesterone/E2 ratio.
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Figure 1. Physical signs (A), % time in the open arms of the EPM (B), % time in the lit
compartment of the LDT box (C) and corticosterone (D) (+SEM) in nicotine-treated male (0
mg/kg n=16; 1.5 mg/kg n=17; 3.0 mg/kg n=12), intact female (0 mg/kg n=18; 1.5 mg/kg n=24;
3.0 mg/kg n=38), and OVX (0 mg/kg n=13; 1.5 mg/kg n=12; 3.0 mg/kg n=13) rats that received
saline or mecamylamine (1.5 or 3.0 mg/kg). Asterisks (*) denote a difference from respective
saline controls, number signs (#) denote a difference from their respective mecamylamine-treated
group, at signs (@) denote a difference from OVX rats in their respective treatment condition,
and the dagger (†) denotes a difference from males and OVX rats in their respective treatment
condition (p < 0.05).
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Figure 2. E2 (A) and progesterone (B) levels (+SEM) during withdrawal produced by
mecamylamine (3.0 mg/kg) in intact females rats that were tested during the proestrus (n=12),
estrus (n=12), metestrus (n=7), and diestrus (n=7) phase of the estrous cycle. Daggers (†) denotes
a significant difference from all other groups (p < 0.05).
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Figure 3. Physical signs (A), % time in the open arms of the EPM (B), % time in the lit
compartment of the LDT box (C) and corticosterone (D) (+SEM) during withdrawal produced by
mecamylamine (3.0 mg/kg) in intact females rats that were tested during the proestrus (n=12),
estrus (n=12), metestrus (n=7), and diestrus (n=7) phase of the estrous cycle. Daggers (†) denotes
a difference from all other groups (p < 0.05).
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Figure 4. E2, and progesterone levels (+SEM) in female rats that displayed high E2/low
progesterone (n=26) or low E2/high progesterone (n=12) that received mecamylamine (3.0 mg/kg)
on test day. Asterisk (*) denotes a significant difference from the other hormone group (p < 0.05).
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Figure 5. Physical signs (A), % time in the open arms of the EPM (B), % time in the lit
compartment of the LDT box (C) and corticosterone (D) (+SEM) in female rats displaying high
E2/low progesterone (n=26) or low E2/high progesterone (n=12) that received mecamylamine (3.0
mg/kg) on test day. Asterisks (*) denote a difference between groups (p < 0.05).
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Figure 6. Physical signs (A), % time in the open arms of the EPM (B), % time in the lit
compartment of the LDT box (C) and corticosterone (D) (+SEM) in nicotine-treated OVX rats that
received vehicle (OVX-veh; 0 mg/kg n=10; 3.0 mg/kg n=8), E2 (OVX-E2; 0 mg/kg n=13 mg/kg;
3.0 mg/kg n=10) or E2+progesterone (OVX-E2+progesterone; 0 mg/kg n=13; 3.0 mg/kg n=13)
that received mecamylamine (0 or 3.0 mg/kg) on the test day. Asterisks (*) denote a difference
from saline controls, number signs (#) denote a difference from OVX-veh and OVX-E2 regardless
of mecamylamine treatment, and the dagger (†) denotes a difference from OVX-veh and OVXE+progesterone rats in their respective treatment condition (p < 0.05).
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